Janus International Group, Inc. JBI 深 沪
等待开盘 05-14 09:30:00 美东时间
5.09
+0.130
+2.62%
华盛通- 最 高5.11
- 今 开4.84
- 成交量 218.68万股
- 最 低 4.82
- 昨 收 4.96
- 总市值 6.94亿
- 52周最高 10.80
- 市盈率 静 13.22
- 换手率 1.60%
- 52周最低 4.26
- 委 比 64.27%
- 总股本 1.36亿
- 历史最高 15.94
- 量 比 1.23
- 振 幅 5.85%
- 历史最低 4.26
- 每 手 1
- 风险率 1.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UBS Maintains Neutral on Janus Intl Gr, Lowers Price Target to $6
UBS analyst John Lovallo maintains Janus Intl Gr (NYSE:JBI) with a Neutral and lowers the price target from $7.25 to $6.
05-13 22:50
Janus International Group shares are trading lower after the company reported mixed Q1 financial results.
Janus International Group shares are trading lower after the company reported m...
05-12 21:09
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
Janus Intl Gr Q1 Adj. EPS $0.01 Misses $0.09 Estimate, Sales $222.700M Beat $219.206M Estimate
Janus Intl Gr (NYSE:JBI) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.09 by 88.89 percent. This is a 92.31 percent decrease over earnings of $0.13 per share from the
05-12 18:58
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Keybanc Maintains Overweight on Janus Intl Gr, Lowers Price Target to $9
Keybanc analyst Jeffrey Hammond maintains Janus Intl Gr (NYSE:JBI) with a Overweight and lowers the price target from $12 to $9.
03-05 21:31
Earnings Scheduled For March 4, 2026
Companies Reporting Before The Bell • Dingdong (Cayman) (NYSE:DDL) is estimated...
03-04 19:11
Janus International Group Acquires Kiwi II Construction For ~$97.2M In Cash
Janus International Group, Inc. (NYSE:JBI) ("Janus" or the "Company"), a leading provider of building product solutions and cutting-edge access control technologies for the self-storage and other commercial and
01-09 05:15
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
